With increasing availability, better affordability and decreasing cost of the technology, the impact and expanding scope of the robotic surgical systems is a game-changer in managing urological cancers. TheHealthSite.com
Global Genitourinary Drugs Market to Reach $41 Billion by 2030. In the changed post COVID-19 business landscape, the global market for Genitourinary Drugs.
Researchers at The University of Texas MD Anderson Cancer have engineered a new model of aggressive renal cell carcinoma (RCC), highlighting molecular targets and genomic events that trigger chromosomal instability and drive metastatic progression.